Efficacy and safety of Sacubitril/Valsartan in improving collateral circulation in hypertensive patients with acute ischemic stroke

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400089459

Enrollment

Unknown

Registered

2024-09-09

Start date

2022-11-15

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke with hypertention

Interventions

Antihypertension by Sacubitril/Valsartan:Sacubitril/Valsartan, 100-200mg qd

Antihypertension by other agents:Other antihypertensive agents, determined by clinical physicians

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age = 40 years; 2. Acute ischemic stroke confirmed by symptoms and signs; 3. Stroke onset within 24-72hours; 4. Systolic blood pressure 140-200mmHg and/or diastolic blood pressure 80-120mmHg; 5. First stroke or pre-stroke mRS<2; 6. Patient/Legally Authorized Representative has signed the Informed Consent form.

Exclusion criteria

Exclusion criteria: 1. Haemorrhagic stroke confirmed by CT 2. Stroke caused by dissection, arteritis, moyamoya disease, tumor metastasis, abnormal coagulation function, hereditary disease 3. Severe stroke (National Institutes of Health Stroke Scale score of =21) 4. Undergoing intravenous alteplase or mechanical thrombectomy 5. Severe heart failure (New York Heart Association class III and IV) or left ventricular ejection fraction <35% 6. Myocardial infarction or unstable angina within the past 3 months 7. Use of Sacubitril/Valsartan within the past 1 month 8. Diagnosed with severe active liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc 9. Diagnosed with severe active kidney disease or renal insufficiency 10. Severe mental disorders and dementia 11. Difficult-to-control hypertension (systolic blood pressure =170mmHg despite use of =4 antihypertensive medications for =6 months) 12. Current participation in another clinical trial 13. Any clinical conditions, in the opinion of the investigator, precludes the adherence to study procedures.

Design outcomes

Primary

Measure	Time frame
Improvement of pulsatility index of the milddle cerebral artery at 90d;New vascular events at day 90;	—

Secondary

Measure	Time frame
mRS distribution at day 90;BP control at day 14;Activity of daily living at day 90;	—

Countries

China

Contacts

Public ContactDing Jing

Zhongshan Hospital, Fudan University

ding.jing@zs-hospital.sh.cn+86 135 0191 7091

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026